We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akouos, Inc., a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, announced it has raised $105 million in an oversubscribed Series B financing.
Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based biotech unveiled the series A round alongside the appointment of a Spark Therapeutics co-founder and other organizational changes.